Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3NIH 3INDUSTRY 3NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Sarcoma 2CNS 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 3Kidney Neoplasms 2Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 54Specimen Handling 48aldesleukin 35Docetaxel 30Biopsy 28Bevacizumab 24Gemcitabine 21Cyclophosphamide 21Cisplatin 21Radiotherapy 19Prednisone 17Sorafenib 16Carboplatin 16sargramostim 15PROSTVAC 15Paclitaxel 14Interferon-alpha 14Sunitinib 13ixabepilone 12cabozantinib 12Immunoglobulin G 12Goserelin 12Disulfides 12fludarabine phosphate 11fludarabine 11Nivolumab 11Fluorouracil 11Chemotherapy, Adjuvant 11pembrolizumab 10bicalutamide 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × vandetanib × Genitourinary × Clear all
NCT02495103 2021-01-26

Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
7 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell

NCT00566995 2018-10-30

Phase II Study of Vandetanib in Individuals With Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
37 enrolled 16 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01372813 2015-10-23

Vandetanib to Treat Advanced Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
3 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡